The European Social Fund Makes News

BRUSSELS, September 22, 2010 – If you're seeking a strong human interest story, then take a
look at the European Social Fund. Far from being a set of dry statistics, the
ESF is the framework for thousands of fascinating tales of individual human
endeavour.

To view the Multimedia News Release, please click:
[...]

Alberto Grua Head of Gr??nenthal Europe and Australia

MILAN, September 22, 2010 – After having handled the worldwide launch of tapentadol, the innovative
drug for the severe acute pain, Alberto Grua has been appointed Gr??nenthal
Europe and Australia Executive Vice President. Beyond the responsibility of
the Gr??nenthal subsidiaries Gr??nin both continents, Grua will be also a
member of the Group Operating Committee of Gr??nenthal Corporation.

[...]

Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus

Santaris Pharma A/S initiates Phase 2a clinical trial with miravirsen (SPC3649) to assess safety and tolerability in treatment-naive patients with chronic Hepatitis C

HOERSHOLM, Denmark and SAN DIEGO, September 22, 2010 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the discovery and development of RNA-targeted therapies, today announced
that it has advanced miravirsen (SPC3649), the [...]

World First in Eczema Treatment

LONDON, September 22, 2010 – Following five years of research and development, Dreamskin Health Ltd is
proud to have launched the world's first range of hydrating, medical-grade
silk garments designed to relieve the itching and irritation of eczema and
dermatitis.

The secret to the new garments is a proprietary biomimetic copolymer
matrix which is firmly [...]

Elsevier Launches International Journal of Surgery Case Reports

New Journal, Included in PubMed Central, Publishes Case Reports Only and Through an Author Pays Model

OXFORD, England, September 22, 2010 – Elsevier, the world-leading publisher of scientific, technical
and medical information products and services together with Surgical
Associates Ltd the Owner of the International Journal of Surgery, announced
today the launch of the International Journal of Surgery [...]

Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium Promus Element(TM) Stent

Nine-month Results From PLATINUM Clinical Program Presented at TCT
NATICK, Massachusetts, September 22, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced data
from its PLATINUM QCA study, which is designed to evaluate the Company's
PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Coronary Stent. The
results provided 30-day and nine-month clinical outcomes and nine-month
quantitative coronary angiography (QCA) and intravascular ultrasound [...]

Abbott’s Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results

Positive Data at Six and Nine Months Affirm Groundbreaking Potential of Abbott's Bioresorbable Vascular Scaffold as a Promising Alternative to Coronary Stenting

ABBOTT PARK, Illinois, September 22, 2010 – Abbott (NYSE: ABT) today announced positive nine-month results from the
first 45 patients enrolled in the second stage of the ABSORB trial. At nine
months, Abbott's bioresorbable vascular [...]

Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients

Phase II Study Published in the New England Journal of Medicine
LONDON and SAN FRANCISCO, September 22, 2010 – AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788),
recently in-licensed from Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL),
significantly improved outcomes of patients with rheumatoid arthritis (RA)
who responded inadequately to ongoing treatment with methotrexate (MTX),
according to phase II study [...]